Plain-English translation of NCT07446998 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
The PLATEAU trial is testing whether a medication called , taken as a daily pill, can help preserve muscle strength and physical function in older adults who are also receiving semaglutide (an injectable weight loss medication). Researchers want to see if combining these two treatments leads to better overall health outcomes than weight loss medication alone, particularly in maintaining the ability to move and function well.
When people lose weight, they often lose muscle along with fat, which can make them weaker and less able to do everyday activities—a problem that's especially concerning for older adults. This trial aims to see if this medication can help people maintain their muscle and strength while losing weight, improving their quality of life.
You likely qualify if…
You likely don't qualify if…
If you enroll, you'll be randomly assigned to receive either the injectable weight loss medication plus the daily pill being tested, or the injectable medication plus a placebo pill (a pill with no active ingredient). You'll take the pill daily for approximately 16 months (476 days) while receiving regular injections. Throughout the study, you'll have clinic visits where researchers will measure your weight, test your physical strength and function, and monitor your safety. A final follow-up visit will occur about 30 days after you stop taking the medication.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States